Barclays
NTLA icon

Barclays’s Intellia Therapeutics NTLA Stock Holding History

Barclays’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-43,000
Closed -$1.18M – 5171
2024
Q1 		$1.18M Sell
43,000
-29,200
-40% -$811K ﹤0.01% 2984
2023
Q4 		$2.2M Buy
+72,200
New +$2.08M ﹤0.01% 2841

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Barclays's NTLA Position: Q2 2026 in Review

Barclays increased its Intellia Therapeutics (NTLA) stake by 2.9% in Q2 2026, buying an estimated $60.6K and bringing the position to 151,569 shares worth $2.56M. The position accounts for ﹤0.01% of the portfolio, ranked #2218.

Barclays first reported a position in NTLA in Q2 2016 and has held it in 41 quarters since. The position peaked at $16.4M in Q4 2021. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Barclays held 151,569 shares of Intellia Therapeutics worth $2.56M as of Q2 2026.
  • Barclays bought 4,327 Intellia Therapeutics shares in Q2 2026, an estimated $60.6K.
  • Intellia Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2218 holding.
  • Barclays first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 41 quarters since.
  • Barclays's Intellia Therapeutics position peaked at $16.4M in Q4 2021.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.